AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early — CEO Sees 'Value-Inflection Period' Ahead

• The enrollment milestone also marks progress in AIM ImmunoTech's broader strategy to advance Ampligen toward late-stage development in pancreatic cancer.
• The company said it is continuing Phase 3 trial planning while expanding its global regulatory and intellectual property footprint.
• AIM ImmunoTech said the planned Phase 3 program is backed by data from a Dutch Named Patient Program and encouraging results from the ongoing DURIPANC study.

Shares of AIM ImmunoTech Inc. (AIM) soared more than 200% in Monday morning’s trade after the company announced that its pancreatic cancer trial hit a key enrollment milestone ahead of schedule.

AIM ImmunoTech announced final patient enrollment in its Phase 2 study of Ampligen (rintatolimod) combined with AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer following FOLFIRINOX treatment.

AIM ImmunoTech shares were up more than 130% in Monday morning’s trade after paring some of the gains.

AIM CEO Says Ampligen Dosing On Track For Completion

AIM ImmunoTech CEO Thomas K. Equels stated that the company is on track to complete the dosing of Ampligen, which should allow the company to evaluate the study's critical primary endpoint of Clinical Benefit Rate (CBR) in December 2026.

CBR measures the percentage of patients who achieve stable disease, a partial response or a complete response six months after starting the combination therapy.

“Together with our ongoing Phase 3 planning efforts, orphan drug designations in the United States and Europe, expanding global intellectual property portfolio, and growing body of positive clinical data, we believe Ampligen is advancing toward a significant value-inflection period for AIM,” Equels said.

AIM Advances Toward Phase 3 Development

The enrollment milestone also marks progress in AIM ImmunoTech's broader strategy to advance Ampligen toward late-stage development in pancreatic cancer.

The company said it is continuing Phase 3 trial planning while expanding its global regulatory and intellectual property footprint. AIM added that the planned Phase 3 program is supported by previously published data from a Dutch government-approved Named Patient Program, as well as encouraging results from the ongoing DURIPANC study.

According to the company, more than 100 pancreatic cancer patients have been treated with Ampligen across these programs, helping the company acquire clinical experience to support the therapy's further development.

AIM’s Ampligen Ebola Presentation Due This Week

AIM ImmunoTech announced last week that it plans to release an on-demand presentation highlighting previously published preclinical data supporting the potential use of Ampligen as both a preventive and early-stage antiviral treatment for Ebola virus disease.

The announcement comes amid rising concern over a Bundibugyo-strain Ebola outbreak in Central and East Africa, a variant that currently has no approved treatment or vaccine.

The company said research conducted at USAMRIID's Biosafety Level 4 laboratories demonstrated Ampligen's potential to address this unmet medical need.

How Did Retail Investors React To AIM Stock?

Retail sentiment on Stocktwits around AIM ImmunoTech trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.

AIM stock is down 14% year-to-date, while AZN stock is down 2%. The Vanguard Extended Market Index Fund ETF (VXF) is up 29% over the past 12 months.

Also See: SMCI Stock Gets Target Boost As Mizuho Cites Agentic AI Demand — Jensen Huang Says 'One Prompt Can Launch A Thousand-Step Journey'

For updates and corrections, email newsroom[at]stocktwits[dot]com.